Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road

Diego A. Adrianzen-Herrera, Aditi Shastri

Research output: Contribution to journalArticlepeer-review

Abstract

A sizable proportion of patients with acute myeloid leukemia (AML) fail to achieve remission. Hematopoietic stem cell transplantation (HSCT) is the only intervention with potential of longterm survival. A recent Acute Leukemia Working Party (ALWP)/ European Society for Blood and Marrow Transplantation (EBMT) analysis reports substantial posttransplant survival gains for patients with active disease who received transplants. Decreased relapse was the largest contributor to survival, a cause for optimism in this challenging population.

Original languageEnglish (US)
Pages (from-to)4167-4170
Number of pages4
JournalClinical Cancer Research
Volume28
Issue number19
DOIs
StatePublished - Oct 1 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road'. Together they form a unique fingerprint.

Cite this